Peptide therapy, decoded.

200+ clinical monographs, interactive dosing calculators, and community reviews — all PubMed-referenced and free to access.

200+ Monographs·14 Clinical Tools·37 Languages·PubMed-Referenced·No Pharmacy Affiliations

Latest Research & Education

Article

Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis

Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant antifibrotic activity in pulmonary fibrosis models by functioning as a PAR-1 antagonist that disrupts the coagulation factor Xa-PAR-1 signaling axis. The peptide inhibited fibroblast invasion and migration with a favorable safety profile—no adverse effects at 0.5 mg/kg/day and only mild hepatomegaly at supratherapeutic doses.

Peptide Publicus Editorial··1 min read
Evidence-based
Guides

ペプチドは安全か:臨床研究の結果

ペプチド医薬品は安全なのか?GLP-1受容体作動薬、BPC-157、成長ホルモン分泌促進ペプチドなど、主要なペプチドの臨床研究データと副作用プロファイルをPMDA承認情報・国内外の論文をもとに解説します。

Peptide Publicus Editorial··1 min read
Evidence-based
Review

Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review

A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, finding selective cytotoxicity against tumor cells via membrane disruption and apoptosis induction, though clinical evidence remains limited to early-phase trials.

Peptide Publicus Editorial··2 min read
Evidence-based
Article

Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial

The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing significant MASH resolution without worsening fibrosis at 24 weeks. FDA granted Breakthrough Therapy designation in January 2026.

Peptide Publicus Editorial··2 min read
Evidence-based
Article

Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial

Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight reduction at 68 weeks in the pivotal TRIUMPH-4 trial — the largest weight loss ever reported for any anti-obesity medication in Phase 3.

Peptide Publicus Editorial··2 min read
Evidence-based
Informational

ペプチドとは何か:体内での仕組みと効果を徹底解説

ペプチドとはアミノ酸が2〜50個程度結合した化合物で、ホルモン・神経伝達物質・抗菌因子として体内で多彩な役割を果たします。本記事では、ペプチドの基本構造、体内での作用メカニズム、医薬品・サプリメントとしての活用、そしてPMDAによる日本独自の規制と市販後調査についてわかりやすく解説します。

Peptide Publicus Editorial··1 min read
Evidence-based

Real Experiences from Real UsersNEW

BPC-157
Worth it

Game-changer for my knee recovery

After 6 weeks of subcutaneous injections, the chronic tendon pain I'd had for 2 years was down to almost nothing. Combined with PT, the results were remarkable.

Verified user · 8 weeks

Semaglutide
Worth it

Steady weight loss, minimal sides

Lost 14 lbs over 3 months on the titration schedule. Nausea was real the first 2 weeks but manageable. Worth it for the appetite control alone.

Verified user · 12 weeks

CJC-1295 + Ipamorelin
Worth it

Best GH stack I've tried

Noticeably better sleep by week 2, improved recovery from training by week 4. Skin quality improved. No water retention like with GHRP-6.

Verified user · 16 weeks

200+

Monographs

14

Interactive Tools

37

Languages

100%

Independent

最新情報をキャッチアップ

臨床アップデート、業界ニュース、新規研究まとめ、ツールリリース情報。

プライバシーを尊重します。いつでも購読解除できます。